Shares of Autolus Therapeutics (NASDAQ: AUTL), a clinical-stage biopharmaceutical company, are on the move after the company announced a new deal with Moderna (NASDAQ: MRNA). Investors excited about Autolus Therapeutics' potential role in Moderna's commercialization of RNA-based therapeutics drove the stock more than 25% higher when the market opened, but the gains have subsided as investors pick apart the details. Autolus Therapeutics' stock price was 13% higher as of 11:18 a.m. EDT on Monday.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting